Marinus Pharmaceuticals’ (MRNS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $27.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also commented on MRNS. Royal Bank of Canada reiterated an outperform rating and set a $24.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, March 6th. StockNews.com lowered Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. Finally, Oppenheimer reiterated a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $21.21.

Marinus Pharmaceuticals Trading Up 2.1 %

NASDAQ MRNS opened at $9.04 on Tuesday. The business has a 50 day simple moving average of $9.57 and a 200 day simple moving average of $8.47. Marinus Pharmaceuticals has a one year low of $5.57 and a one year high of $11.26. The stock has a market capitalization of $493.95 million, a P/E ratio of -3.44 and a beta of 0.93. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The firm had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. During the same period last year, the business posted ($0.76) EPS. Research analysts expect that Marinus Pharmaceuticals will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. Point72 Asset Management L.P. purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth approximately $13,990,000. BlackRock Inc. lifted its position in Marinus Pharmaceuticals by 245.4% during the second quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company’s stock valued at $42,330,000 after purchasing an additional 2,769,357 shares in the last quarter. Eventide Asset Management LLC lifted its position in Marinus Pharmaceuticals by 42.8% during the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock valued at $36,466,000 after purchasing an additional 1,356,800 shares in the last quarter. Jennison Associates LLC lifted its position in Marinus Pharmaceuticals by 58.4% during the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after purchasing an additional 1,089,913 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Marinus Pharmaceuticals by 415.7% during the fourth quarter. Millennium Management LLC now owns 1,082,759 shares of the biopharmaceutical company’s stock valued at $4,309,000 after acquiring an additional 872,782 shares during the period. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.